149 related articles for article (PubMed ID: 6911148)
21. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
[TBL] [Abstract][Full Text] [Related]
22. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
23. Alternative pathway of complement is activated during in vitro ventricular assist.
Chen JC; Huynh TN; Serna DL; Sun CP; Ha H; Steward E; Webster S; Brenner M
J Investig Med; 1999 Nov; 47(9):502-6. PubMed ID: 10572381
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
Leijh PC; van den Barselaar MT; Daha MR; van Furth R
J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
[TBL] [Abstract][Full Text] [Related]
25. The alternative complement pathway in chickens. Purification of factor B and production of a monospecific antibody against it.
Koch C
Acta Pathol Microbiol Immunol Scand C; 1986 Dec; 94(6):253-9. PubMed ID: 3646826
[TBL] [Abstract][Full Text] [Related]
26. Identification of Complin, a novel complement inhibitor that targets complement proteins factor B and C2.
Kadam AP; Sahu A
J Immunol; 2010 Jun; 184(12):7116-24. PubMed ID: 20483772
[TBL] [Abstract][Full Text] [Related]
27. Solid phase activation of alternative pathway of complement by beta-1,3-glucans and its possible role for tumour regressing activity.
Hamuro J; Hadding U; Bitter-Suermann D
Immunology; 1978 Apr; 34(4):695-705. PubMed ID: 721136
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
29. Activation of the complement system and leukocyte recruitment by Tityus serrulatus scorpion venom.
Bertazzi DT; de Assis-Pandochi AI; Talhaferro VL; Caleiro Seixas Azzolini AE; Pereira Crott LS; Arantes EC
Int Immunopharmacol; 2005 Jun; 5(6):1077-84. PubMed ID: 15829423
[TBL] [Abstract][Full Text] [Related]
30. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
[TBL] [Abstract][Full Text] [Related]
31. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation.
Lévi-Strauss M; Mallat M
J Immunol; 1987 Oct; 139(7):2361-6. PubMed ID: 3655365
[TBL] [Abstract][Full Text] [Related]
32. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
33. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships.
Kaplan AP; Ghebrehiwet B; Silverberg M; Sealey JE
Crit Rev Immunol; 1981 Sep; 3(1):75-93. PubMed ID: 7047077
[TBL] [Abstract][Full Text] [Related]
34. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
35. Activation of bovine monocytes and neutrophils by the Bb fragment of complement factor B: demonstration by the uptake of 3H-deoxyglucose.
Sethi MS; Tabel H; Misra V
Can J Vet Res; 1990 Jan; 54(1):106-12. PubMed ID: 2306658
[TBL] [Abstract][Full Text] [Related]
36. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
37. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
[TBL] [Abstract][Full Text] [Related]
38. Human complement factor B: functional properties of a recombinant zymogen of the alternative activation pathway convertase.
Schwaeble W; Lüttig B; Sokolowski T; Estaller C; Weiss EH; Meyer zum Büschenfelde KH; Whaley K; Dippold W
Immunobiology; 1993 Jul; 188(3):221-32. PubMed ID: 8225386
[TBL] [Abstract][Full Text] [Related]
39. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
[No Abstract] [Full Text] [Related]
40. A new apoptotic pathway for the complement factor B-derived fragment Bb.
Uwai M; Terui Y; Mishima Y; Tomizuka H; Ikeda M; Itoh T; Mori M; Ueda M; Inoue R; Yamada M; Hayasawa H; Horiuchi T; Niho Y; Matsumoto M; Ishizaka Y; Ikeda K; Ozawa K; Hatake K
J Cell Physiol; 2000 Nov; 185(2):280-92. PubMed ID: 11025450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
